Annuncio pubblicitario
Italia markets closed
  • Dow Jones

    37.848,37
    -612,55 (-1,59%)
     
  • Nasdaq

    15.440,68
    -272,07 (-1,73%)
     
  • Nikkei 225

    37.628,48
    -831,60 (-2,16%)
     
  • EUR/USD

    1,0720
    +0,0020 (+0,18%)
     
  • Bitcoin EUR

    59.548,04
    -832,84 (-1,38%)
     
  • CMC Crypto 200

    1.377,43
    -5,15 (-0,37%)
     
  • HANG SENG

    17.284,54
    +83,27 (+0,48%)
     
  • S&P 500

    5.008,79
    -62,84 (-1,24%)
     

Why Shares Of Moderna Are Up By 7% Today?

Moderna Video 13.04.21.

Moderna Says That Its Vaccine Is Not Linked To Rare Blood Clots

Shares of Moderna gained solid upside momentum after the company stated that available safety data on its coronavirus vaccine did not suggest an association with cerebral venous sinus thrombosis (CVST) or thrombotic events. More than 64.5 million doses of Moderna’s vaccine have been administered globally.

Moderna decided to issue this statement after U.S. recommended to pause the use of Johnson & Johnson COVID-19 vaccine as six women developed blood clots after receiving the vaccine. Previously, AstraZeneca faced problems with rare blood clots, and some countries decided to limit the use of the company’s vaccine.

ANNUNCIO PUBBLICITARIO

While blood clots appear to be a very rare side effect (more than 6.8 million doses of Johnson & Johnson’s vaccine have been administered in the U.S., and only six cases of blood clots potentially linked to vaccine have been reported so far), Johnson & Johnson’s vaccine will surely suffer a PR blow.

This is a negative development for the mass vaccination program but a positive development for Moderna which may gain additional market share due to problems of AstraZeneca and Johnson & Johnson.

What’s Next For Moderna?

The bull case for Moderna is getting stronger. Its coronavirus vaccine has avoided any notable problems, and the company’s shares stand ready to gain from the problems of its competitors.

Currently, analysts expect that the company will report earnings of $21.85 per share in 2021 and $14.87 per share in 2022 so the stock is trading at about 10 forward P/E for 2022.

However, it is not clear whether revenue from the coronavirus vaccine will be recurring. If data suggests that people will need regular vaccinations, like in the case of an ordinary flu, Moderna shares will look very cheap at current levels.

In the near term, Moderna stock will likely continue to benefit from Johnson & Johnson and AstraZeneca problems.

For a look at all of today’s economic events, check out our economic calendar.

This article was originally posted on FX Empire

More From FXEMPIRE: